Natera (NASDAQ:NTRA) Given New $135.00 Price Target at Sanford C. Bernstein

Natera (NASDAQ:NTRA) had its price target raised by Sanford C. Bernstein from $125.00 to $135.00 in a research report report published on Wednesday, Benzinga reports. The firm currently has an outperform rating on the medical research company’s stock.

Several other equities analysts have also commented on NTRA. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research report on Friday, October 25th. TD Cowen increased their price objective on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, August 9th. UBS Group decreased their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $150.00 price objective on shares of Natera in a research report on Friday, September 13th. Finally, The Goldman Sachs Group raised their price target on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $125.69.

Natera Stock Performance

NTRA stock opened at $126.73 on Wednesday. The firm has a market cap of $15.67 billion, a price-to-earnings ratio of -51.73 and a beta of 1.53. The firm has a 50-day simple moving average of $123.31 and a two-hundred day simple moving average of $111.82. Natera has a one year low of $37.67 and a one year high of $133.54. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.39. The business had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company’s quarterly revenue was up 58.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.97) earnings per share. On average, equities analysts forecast that Natera will post -1.96 EPS for the current fiscal year.

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 256 shares of the firm’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total transaction of $30,737.92. Following the sale, the insider now owns 111,891 shares of the company’s stock, valued at $13,434,752.37. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CFO Michael Burkes Brophy sold 1,238 shares of Natera stock in a transaction on Monday, October 28th. The shares were sold at an average price of $118.21, for a total value of $146,343.98. Following the sale, the chief financial officer now owns 71,471 shares of the company’s stock, valued at approximately $8,448,586.91. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Solomon Moshkevich sold 256 shares of Natera stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total transaction of $30,737.92. Following the completion of the sale, the insider now directly owns 111,891 shares in the company, valued at $13,434,752.37. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 48,298 shares of company stock valued at $5,921,336 in the last 90 days. 7.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Natera

Institutional investors have recently added to or reduced their stakes in the stock. Itau Unibanco Holding S.A. acquired a new stake in Natera in the 2nd quarter valued at $28,000. Quarry LP lifted its holdings in Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares in the last quarter. Tobam purchased a new position in Natera in the 2nd quarter valued at $74,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in Natera in the 1st quarter valued at $83,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.